{"id":"c81e0330-37da-4bff-abf4-8b226ff2353f","arxiv_id":"2506.06915","paper_version":1,"verdict":"CONDITIONAL","confidence":"MODERATE","novelty_score":1.0,"correctness_risk":"medium","formal_verification":"none","parameter_count":0,"one_line_summary":"A comprehensive model-centric review of graph neural network methods and applications in AI-aided drug discovery, from molecular representation to synthesis planning.","lead":"Molecules are naturally graphs, and this review maps how graph neural networks are used across the drug discovery pipeline, from property prediction to synthesis planning. It is a broad, model-centric survey that could help researchers navigate a fragmented field, though it offers no new experimental results.","discovery_kind":"review","skeptic_critique":{"model":"deepseek-v4-flash","headline":"\"Comprehensive overview\" rests on an undocumented selection process; a coverage audit is needed before the map can be trusted.","rationale":"The reader's weakest assumption is that the review's selection of papers is representative and that its model-centric taxonomy captures the dominant methodological lines. That is exactly the load-bearing concern I identified: the manuscript claims comprehensiveness without describing any systematic selection protocol. I agree with the reader's identification. I did not find an internal contradiction in the methodological chapters; the formulas and architecture summaries are mostly standard presentations, with minor typos (e.g., the GCN normalization shorthand and the LSTM permutation-invariance wording) that do not threaten the central claim as strongly as the coverage gap. I also credit the review's organizational clarity and the breadth of topics it does cover; these are real assets. The single check that would settle the concern is a coverage audit on one representative application section. If the audit shows high coverage of principal methods and no factual table errors, the conditional verdict can stand as a recommendation to accept with a methodological caveat. If coverage is low, the paper should be revised to either implement a search protocol or explicitly present itself as a curated, perspective-driven review rather than a comprehensive one. Therefore I leave the reader's CONDITIONAL verdict unchanged.","tokens_in":47088,"tokens_out":5082,"duration_ms":60098,"concrete_test":"Audit Section 4 (virtual screening) as a test bed. Build a reproducible corpus by querying arXiv and PubMed for (graph neural network OR GNN) AND (docking OR binding affinity OR binding site) over 2018–2025, deduplicating, and coding all unique papers against the review's taxonomy. Then compute (i) the fraction of top-cited methods from the corpus that appear in Section 4, and (ii) the number of benchmark-table entries whose values differ from the cited original papers. If coverage of the principal method families is below about 80% or any table entry is inconsistent with its source, the 'comprehensive overview' claim should be narrowed to 'selected overview'; if coverage is high and entries match, the concern does not land.","verdict_should_be":"UNCHANGED","load_bearing_attack":"The paper's central claim—that it gives 'a comprehensive overview' of GNNs in drug discovery—is load-bearing because the review's stated value is to organize the field into a reliable model-centric map. The manuscript never describes how the included works were selected: Section 1.2 gives scope and organization but no search strategy, inclusion/exclusion criteria, or coverage target. Without a protocol, the reader cannot distinguish a comprehensive survey from a curated sample, and any bias in selection or taxonomy becomes invisible. This matters concretely: Tables 2, 4, 9–12 and the section-level maps (Sections 2.1–2.5, 3–7) are presented as representative of the field; if major method families or benchmark entries are omitted or mis-assigned, newcomers will draw wrong conclusions about which approaches are established. The concern is not that editorial judgment is illegitimate; it is that an explicit claim of comprehensiveness requires a bounded, reproducible basis for that judgment, and none is given.","agreement_with_reader":"agree"},"referee_report":{"model":"deepseek-v4-flash","summary":"This manuscript is a review of graph neural network (GNN) methods in AI-aided drug discovery (AIDD). It proposes a model-centric taxonomy—spectral/spatial GNNs, symmetry-aware (invariant/equivariant) GNNs, large/deep GNNs, graph generative models, and graph editing with reinforcement learning—and then surveys applications in molecular property prediction, virtual screening, molecular generation, biomedical knowledge graphs, and chemical synthesis. The review also covers uncertainty quantification, explainability, pretraining, and graph transformers, and closes with practical challenges and future directions. The stated goal is to provide a comprehensive, structured overview for both chemistry/biology researchers and computational scientists.","tokens_in":47259,"tokens_out":6550,"duration_ms":70174,"significance":"If the accuracy and completeness issues are addressed, this review could be a useful entry point for researchers entering GNN-based drug discovery. Its strengths are the breadth of topics, the model-centric organization, and the compact comparative tables (e.g., Tables 2, 3, 5, 9, 11) that condense a large literature. The inclusion of less commonly surveyed areas such as conformal prediction, evidential deep learning, and counterfactual explainability adds value beyond existing reviews. The paper does not provide code or machine-checked proofs, so its value rests on the correctness and representativeness of its narrative, equations, and tables. At present, the undocumented basis for the ‘comprehensive’ claim and several technical/factual errors prevent the manuscript from being fully reliable as a field map, but these issues are fixable within the scope of a major revision.","major_comments":[{"comment":"The abstract and Section 1.2 claim a ‘comprehensive overview,’ but the review never specifies how the covered literature was selected: there is no search strategy, inclusion/exclusion criteria, time window, or coverage target. Tables 2, 4, 9–12 and the section-level maps in Sections 2–7 are therefore presented as representative without a reproducible basis, so a reader cannot distinguish a comprehensive survey from a curated sample. Please add a short methodology paragraph and, ideally, a coverage audit that names the major model families and benchmark datasets considered and states why any omissions were made. This is not a demand for a formal systematic review; it is a request to bound the claim of comprehensiveness.","section":"1.2"},{"comment":"The MPNN reformulation of GCN is internally inconsistent. The text defines Message m_uv = h_u, Aggregate m_v = Σ_{u∈N(v)} m_uv/√(d_u d_v) + h_v, and Update h_v = σ(W m_v). The ‘more compact’ form then writes h_v = σ(Σ_{u∈N(v)∪{v}} m_uv W h_u / √(d_u d_v)), which multiplies h_u by both m_uv and W and does not follow from the preceding three equations. The intended expression is presumably σ(Σ_{u∈N(v)∪{v}} W h_u / √(d_u d_v)) with the appropriate normalization. Since Section 2 is the methodological foundation of the review, these equations need to be corrected.","section":"2.1.2"},{"comment":"The data-imbalance discussion contains a factual error: it states that ‘in the FreeSolv dataset 205, most compounds are recorded as active,’ but FreeSolv is a regression benchmark of experimental hydration free energies and has no active/inactive labels; Table 8 itself lists FreeSolv as a regression task (R). This mischaracterizes a standard benchmark and weakens the illustration of class imbalance. Please replace the example with a genuinely imbalanced classification dataset (e.g., HIV or Tox21) and align the text with Table 8.","section":"3.1.4.1"}],"minor_comments":[{"comment":"In the energy-based model paragraph, the partition function is written as Z = exp∫(-E(x)) dx; it should be Z = ∫ exp(-E(x)) dx.","section":"2.4.1.2"},{"comment":"Several typos and name errors should be corrected: ‘Glebsch-Gorden’ should be ‘Clebsch–Gordan’ (Section 2.2.2); ‘Victor et al. 48’ referring to EGNN should be ‘Satorras et al.’ (Section 2.2.3); and the Section 3.3 heading ‘Blak-box’ should be ‘black-box.’","section":"2.2.2, 2.2.3, 3.3"},{"comment":"In the Transformer equations, the notation is inconsistent: V_i = W_V H_I^T and H_i = Σ_j α_ij V_j should use consistent token indices, and the softmax denominator is written ambiguously. Please align the notation with the standard self-attention formula.","section":"2.3.2.1"},{"comment":"The text says PCBA contains 125 biological targets, while Table 8 reports 128 tasks; Table 8 also labels MUV as ‘R’ (regression) although MUV is a classification benchmark. Please reconcile these numbers and task labels.","section":"3.1.1.3, Table 8"},{"comment":"Table 1 lists ‘SCNN21’ and the text attributes the formulation to Shuman et al. [21]; if reference 21 is the Shuman review, the SCNN model itself is usually attributed to Bruna et al. Please check the citation and the attribution.","section":"Table 1"}],"recommendation":"major_revision","confidential_remarks":"The manuscript would benefit from a careful copyediting pass; the number of typos and inconsistent cross-references is above what one expects at submission. I also noticed that several ‘representative’ examples in Sections 3–5 appear to draw heavily from the authors’ own prior work; for a review claiming comprehensiveness, this selection bias should be balanced by citing independent work on the same tasks. These issues are fixable and do not by themselves warrant rejection. The topic fits the journal; if the methodology for the comprehensiveness claim and the technical/factual errors are addressed, I would support publication."},"author_rebuttal":null,"desk_editor":{"model":"deepseek-v4-flash","letter":"The paper is a solid, well-organized review that gives a model-centric map of GNN methods across drug-discovery tasks. If you want a single document that connects geometric GNNs, graph transformers, pretraining, generative models, and applications like screening, generation, knowledge graphs, and synthesis, this is a good starting point. The breadth is real, and the mathematical background sections are mostly correct and readable.\n\nThe genuinely new thing here is the organizing frame: not task-by-task, but model-centric, which helps expose how the same architectural ideas recur across property prediction, generation, and synthesis. The tables, such as comparing ZINC MAE for graph transformers and listing UQ and XAI methods, are useful reference material.\n\nThe soft spots, in proportion. The biggest is that the abstract and Section 1.2 promise a 'comprehensive overview,' but the manuscript never describes how the included works were chosen—no search strategy, no inclusion/exclusion criteria, no coverage target. That means the comprehensiveness claim is not auditable. The paper is better described as a curated selection by a knowledgeable group, which is legitimate, but the claim needs to be softened or substantiated. This is load-bearing because the value of a review map depends on the reader trusting the selection. On a second pass, the GCN message-passing equations in Section 2.1.2 are internally inconsistent (the compact form uses a different aggregation than the expanded form), and there are scattered typos, including 'Blak-box' in the Section 3.3 title. These are fixable but a referee should demand a cleanup. The self-citation pattern in the selected examples is noticeable but not disqualifying; the cited work is real and relevant, though weighting examples toward your own models without disclosure is a bias.\n\nThe central argument holds up: GNNs are broadly useful in drug discovery, and a model-centric presentation helps organize a scattered literature. The missing selection protocol is a real deficiency, but not a fatal one. I would view the paper positively if the authors added a methodology paragraph and corrected the technical errors.\n\nThis paper is for newcomers and practitioners wanting a structured orientation, not for experts seeking new results. It deserves peer review with revisions, not a desk reject.\n\nMy vote: engage it.","headline":"A useful curated tour of GNNs in drug discovery, but the 'comprehensive' claim is under-supported; worth peer review with revisions.","tokens_in":47764,"tokens_out":2609,"would_cite":true,"duration_ms":30129,"reading_group":"maybe","serious_thinker":"yes","would_accept_peer_review":true},"rs_alignment":null,"lean_confirmation":null,"pith_extraction":{"msc":[],"pacs":[],"model":"deepseek-v4-flash","headline":"Graph neural networks supply the common backbone of AI-aided drug discovery, from property prediction to synthesis planning.","keywords":["graph neural networks","drug discovery","molecular property prediction","virtual screening","molecular generation","knowledge graphs","synthesis planning","equivariant GNNs"],"falsifier":"A reader could check the review's benchmark tables—for example, the ZINC test MAE values in Table 4 and the QM9/MD17 errors in Table 2—against the original model reports; if a substantial fraction of entries are not reproducible, the reliability of the field map collapses. A systematic literature scan for a major GNN family absent from the taxonomy, such as generative diffusion models or large-language-model-based molecular agents, would directly test the comprehensiveness claim.","tokens_in":46896,"feed_emoji":"💊","tokens_out":6567,"duration_ms":61959,"temperature":0.7,"pith_summary":"This review sets out to show that graph neural networks are not just one technique among many in AI-aided drug discovery but a unifying modeling language for the field. Its central claim is that molecules are naturally graph-structured, so message-passing networks can serve as the common backbone for property prediction, virtual screening, molecular generation, biomedical knowledge graphs, and synthesis planning. By organizing the literature around model families rather than tasks, it makes the structural logic of GNN methods explicit and identifies the practical bottlenecks—data scarcity, label noise, over-smoothing, over-squashing, and black-box behavior—that block real-world deployment. The takeaway is that diverse successes share a small set of architectural ideas: local message passing, symmetry-aware geometric updates, graph-level readouts, pretraining, and graph editing with reinforcement learning.","feed_headline":"Graph neural networks unify drug discovery's five core tasks","feed_subtitle":"A model-centric review shows how message passing, geometry, and pretraining connect property prediction to synthesis planning.","key_machinery":"The central machinery is the Message Passing Neural Network (MPNN) abstraction, which reduces a graph neural network to four functions: message, aggregation, update, and readout. Nearly every model reviewed, from GCN and GAT to SchNet, DimeNet, GemNet, EGNN, and graph transformers, is presented as an instance or extension of this framework. The review uses MPNN as the organizing lens: symmetry-aware variants modify the message function to respect rotations and translations, scalable variants modify aggregation and update to avoid over-smoothing and over-squashing, and generative and reinforcement-learning variants replace the readout with decoding, editing, or value functions.","core_discovery":"On the paper's own terms, the central discovery is that the message-passing abstraction—a graph neural network built from message, aggregation, update, and readout functions—is expressive enough to cover the full range of drug-discovery tasks. The review documents a progression from spectral and spatial graph convolutions, through internal-coordinate, tensor-product, and vector-based equivariant GNNs, to large-scale graph transformers and pretraining schemes. It argues that this progression follows the constraints real molecules impose: rotational symmetry, three-dimensional geometry, chirality, scalability, uncertainty, and interpretability. If that is right, progress in drug-discovery AI is largely progress in graph representation learning, and task-specific models are special cases of a common graph-based design space.","pith_inferences":["Beyond the paper, the model-centric taxonomy suggests a testable hypothesis: a benchmark spanning property prediction, docking, generation, and retrosynthesis with shared graph backbones would reveal more cross-task transfer than current task-siloed leaderboards show.","An implicit extension is that foundation-model-style pretraining on molecular graphs could eventually absorb the review's separate categories—geometric GNNs, graph transformers, and generative models—into a single architecture family.","A practical extension would be to report conformal prediction intervals and epistemic uncertainty alongside every GNN property prediction, turning the review's reliability discussion into a reporting standard.","The chirality-aware discussion points to a clean test: an equivariant GNN that respects rotations but not reflections should distinguish enantiomers that ordinary two-dimensional GNNs cannot, which is directly checkable on datasets with R/S labels."],"forward_implications":["If GNNs are the common backbone, then improvements in one task—such as better geometric message passing for property prediction—should transfer to virtual screening and synthesis planning, because the same graph-representation machinery underlies all of them.","Symmetry-aware and chirality-aware GNNs become necessary components for any task where three-dimensional structure determines function, making equivariant design a default rather than an option.","Scaling GNNs with graph-transformer architectures and pretraining on unlabeled molecular data should reduce the field's dependence on scarce, noisy experimental labels.","Uncertainty quantification and explainability stop being optional additions; they become part of the reliability case a model must make before entering real screening or lead-optimization decisions.","Graph editing combined with reinforcement learning closes the loop from prediction to design, turning learned representations into molecules that satisfy specific objectives."],"supporting_citations":[{"why":"Supplies the MPNN abstraction that the review uses to frame nearly all spatial GNN architectures.","marker":"[25]"},{"why":"Defines GCN, the bridge between spectral and spatial message passing that anchors the basic-architecture discussion.","marker":"[23]"},{"why":"Introduces distance-based continuous filters and radial basis embeddings, the starting point for internal-coordinate invariant GNNs.","marker":"[36]"},{"why":"Adds angle-aware directional message passing, the representative second-order geometric GNN.","marker":"[37]"},{"why":"Presents the centrality, spatial, and edge encodings that anchor the Laplacian-free graph-transformer section.","marker":"[107]"},{"why":"Demonstrates large-scale graph-transformer pretraining on molecular graphs, central to the pretraining strategies discussion.","marker":"[130]"},{"why":"Shows a symmetry-aware structure model scaled to biomolecular structure prediction, evidence for the practical reach of equivariant architectures.","marker":"[54]"},{"why":"Provides conformal prediction, the framework the review highlights for statistically valid uncertainty intervals in property prediction.","marker":"[269]"}],"fun_headline_variants":["GNNs unify drug discovery's five core tasks","Message passing links all five drug discovery tasks","A single graph model family spans five drug discovery tasks","From property prediction to synthesis: GNNs do it all","Five drug discovery tasks, one graph neural network approach"],"cache_read_input_tokens":3200,"weakest_assumption_plain":"The review's claims of comprehensiveness rest on the authors' editorial selection of papers, since no systematic search or inclusion criteria are specified; if representative method families are missing or misclassified, the field maps and benchmark tables could mislead.","fun_headline_variants_meta":{"raw":{"variants":["GNNs unify drug discovery's five core tasks","Message passing links all five drug discovery tasks","A single graph model family spans five drug discovery tasks","From property prediction to synthesis: GNNs do it all","Five drug discovery tasks, one graph neural network approach"]},"model":"deepseek-v4-flash","effort":"low","cost_usd":0.001369,"raw_usage":{"total_tokens":5513,"prompt_tokens":868,"completion_tokens":4645,"prompt_tokens_details":{"cached_tokens":384},"prompt_cache_hit_tokens":384,"prompt_cache_miss_tokens":484,"completion_tokens_details":{"reasoning_tokens":4568}},"tokens_in":484,"tokens_out":4645,"duration_ms":34467,"temperature":1.0,"reasoning_tokens":4568,"cache_read_input_tokens":384,"cache_creation_input_tokens":0},"cache_creation_input_tokens":0},"created_at":"2026-08-07T05:46:04.070297+00:00","model_set":{"reader":"deepseek-v4-flash"},"falsifier":"A reader could check the review's benchmark tables—for example, the ZINC test MAE values in Table 4 and the QM9/MD17 errors in Table 2—against the original model reports; if a substantial fraction of entries are not reproducible, the reliability of the field map collapses. A systematic literature scan for a major GNN family absent from the taxonomy, such as generative diffusion models or large-language-model-based molecular agents, would directly test the comprehensiveness claim.","supporting_citations":[{"cited_title":"Algorithm for reaction classification","cited_arxiv_id":null,"evidence_quote":"Supplies the MPNN abstraction that the review uses to frame nearly all spatial GNN architectures."},{"cited_title":"Graph Neural Networks for the Prediction of Substrate-Specific Organic Reaction Conditions","cited_arxiv_id":"2007.04275","evidence_quote":"Presents the centrality, spatial, and edge encodings that anchor the Laplacian-free graph-transformer section."}],"review_version":1}